Germany · Delayed Price · Currency is EUR Poxel Company Description
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases.
It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction.
The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan.
It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications.
The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin.
Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
| Country | France |
| Founded | 2009 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 6 |
| CEO | Nicolas Trouche |
Contact Details
Address: Immeuble Le Sunway Lyon, Auvergne 69007 France | |
| Phone | 33 1 44 71 94 94 |
| Website | poxelpharma.com |
Stock Details
| Ticker Symbol | 7PO |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nicolas Trouche | Chief Executive Officer |
| Fanny Bosa | Chief Financial Officer |
| Arthur Rouille | Head of Investor Relations |